Mounjaro and Zepbound: same drug, different names. Here is why
Mounjaro and Zepbound are both Eli Lilly's tirzepatide. Same molecule, same doses, different brands sold for different indications. The marketing split is regulatory, not pharmacological.
Why we wrote this. The brand split confuses readers who think Zepbound is a different molecule. Answering the question explicitly stops one of the most common misreadings of GLP-1 trial coverage.
If you've been reading about GLP-1 weight-loss drugs, you've probably seen Mounjaro and Zepbound used almost interchangeably. They are the same molecule: tirzepatide, a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. The brand split is a regulatory and marketing decision, not a pharmacological one.
Same molecule, same doses
Both brand presentations contain identical tirzepatide active ingredient at the same set of dose strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg per weekly subcutaneous injection. Pharmacokinetics are identical. The pens are administered the same way.
Different brand, different labelled indication
Mounjaro is the brand Eli Lilly uses for the type-2 diabetes indication. Zepbound is the brand the FDA approved in November 2023 for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity, and in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity.
In the EU and EEA, the EMA authorised Mounjaro for both type-2 diabetes and weight management under a single brand; there is no Zepbound presentation. The MHRA in the UK follows the same pattern. The dual-brand split (Mounjaro for diabetes, Zepbound for obesity) is therefore a US-specific commercial choice that lets each indication carry its own marketing, formulary placement and patient-assistance programme.
Why split the brands at all
Three reasons usually cited. First, insurance and formulary coverage: a payer covering tirzepatide for diabetes does not automatically cover it for obesity, and a single-brand product would force more case-by-case approvals. Second, patient-assistance programmes are easier to administer with branded clarity. Third, marketing: the obesity audience and the diabetes audience overlap but do not match, and Eli Lilly is reaching them with different messaging.
The trade-off is that prescribers have to track two brand names, pharmacies dispense from two SKUs, and the resulting confusion sometimes lets compounded or grey-market "tirzepatide" pass as a generic that is actually neither product.
What this means in practice
If you are reading about weight-loss tirzepatide trial data (SURMOUNT-1 through SURMOUNT-5, SURMOUNT-OSA, SUMMIT), the molecule under study is the same one in any Mounjaro or Zepbound pen at the same dose. Effect sizes, safety signals and the SURMOUNT-5 head-to-head against semaglutide apply equally to either brand at the same dose.
What is not the same: brand-name pricing, insurance coverage, and the legality of import. Country-by-country status is on the regulation pages.
Frequently asked
Is Mounjaro the same drug as Zepbound?
Yes. Both are tirzepatide at the same dose strengths and the same once-weekly subcutaneous injection regimen. The brand difference reflects the labelled indication (Mounjaro for type-2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea) and is a US-specific commercial decision.
Can I switch from one brand to the other?
Clinically it is the same molecule at the same dose. Whether your insurance or pharmacy will support the switch is a separate question, and the answer depends on your plan, indication, and country. Discuss with your prescriber.
Why isn't Zepbound available in the EU?
Because the EMA chose to authorise tirzepatide for both type-2 diabetes and weight management under a single brand (Mounjaro), which makes a separate obesity brand unnecessary. The EMA approach is the more common one internationally; the US dual-brand split is the outlier.